



35           Understanding the mechanisms of hypoblast development and its role in the  
36 implantation is critical for improving farm animal reproduction, but it is hampered by the lack of  
37 research models. Here we report that a chemical cocktail (FGF4, BMP4, IL-6, XAV939, and  
38 A83-01) enables de novo derivation and long-term culture of bovine extraembryonic endoderm  
39 cells (bXENs). Transcriptomic and epigenomic analyses confirmed the identity of bXENs and  
40 revealed that they resemble hypoblast lineages of early bovine peri-implantation embryos.  
41 We showed that bXENs help maintain the stemness of bovine ESCs and prevent them from  
42 differentiation. In the presence of a signaling cocktail sustaining bXENs, the growth and  
43 progression of epiblasts are also facilitated in the developing pre-implantation embryo.  
44 Furthermore, through 3D assembly of bXENs with bovine ESCs and TSCs, we developed an  
45 improved bovine blastocyst like structure (bovine blastoid) that resembles blastocyst. The  
46 bovine XENs and blastoids established in this study represent accessible *in vitro* models for  
47 understanding hypoblast development and improving reproductive efficiency in livestock species.

48

49

## 50 **Introduction**

51           During the mammalian pre-implantation development, the first lineage differentiation  
52 specifies the inner cell mass (ICM) and trophoblast (TE) in the blastocyst; the ICM further  
53 differentiates into epiblast and hypoblast (or primitive endoderm) in blastocyst. Subsequently,  
54 hypoblast or primitive endoderm gives rise to the yolk sac by implantation and is critical to  
55 support early conceptus development by producing a spectrum of serum proteins, generating  
56 early blood cells, and transporting nutrient from the uterus to the embryo (1-3). The  
57 development of hypoblast is a very conserved process although its developmental timing varies  
58 among mammalian species. In cattle, the hypoblast specifies in day 8 blastocysts, and  
59 differentiates into yolk sac during implantation around day 18-23. The involution of yolk sac  
60 occurs 40 days postfertilization which coincides with the formation of the placenta (4-6). Particularly,  
61 hypoblast undergoes dynamic lineage development, which is coordinate with a period of rapid  
62 growth and elongation of embryo from spheroid form at day 9-11, to elongated form at day 12-  
63 14 to a filamentous form at day 16 till implantation (7), when majority of pregnancy loss occur  
64 (8-10). Proper hypoblast development and function are pivotal for the success of pregnancy,  
65 however, our knowledge of hypoblast development, particularly in ruminant species, is limited  
66 due to technical and logistic difficulties associated with *in vivo* experiments and a lack of  
67 manipulatable cell culture models. Furthermore, whether and how extraembryonic tissues  
68 support the development of pre-implantation epiblast remain largely unknown.

69           Extraembryonic endoderm cells (XENs) are established from primitive endoderm of early  
70 embryos and represent valuable tools for studying hypoblast lineage differentiation and function  
71 during embryogenesis (11, 12). To date, the XENs have been established in multiple species  
72 including mice (12), porcine (13, 14), monkey (15), and humans (16). Notably, signaling  
73 pathways inducing XENs vary extensively among different mammals. Mouse XENs can be  
74 captured from ESCs via retinoic acid and Activin-A (17), while human hypoblast has been  
75 induced from naïve pluripotent stem cells dependent of FGF signaling (18) as well as a  
76 chemical cocktail (BMPs, IL-6, FGF4, A83-01, XAV939, PDGF-AA, and retinoic acid) (19). In the  
77 domestic species, porcine XENs can be derived from blastocysts using either LIF/FGF2 or

78 LCDM (LIF, CHIR99021, (S)-(+)-dimethindene maleate, and minocycline hydrochloride)  
79 condition (13, 14). Attempts to establish bovine XENs from blastocysts have also identified  
80 FGF2 as a facilitator, but the resultant cells could not be maintained in long-term culture with  
81 limited characterization (20, 21). Thus far, the authentic bovine XENs have not been established  
82 yet.

83 In this study, we discovered that a modified chemical cocktail (FGF4, BMP4, IL-6,  
84 XAV939, and A83-01) supports de novo derivation and long-term culture of bovine XENs. We  
85 then attempted to use bovine XENs model epiblast and hypoblast lineage crosstalk and found  
86 that bovine XENs promote growth and stemness of bovine embryonic stem cells (ESCs). This is  
87 further confirmed during pre-implantation embryo development by supplement signaling cocktail  
88 sustaining bovine XENs in *in vitro* embryo culture. We observed that the growth and progression  
89 of epiblasts are facilitated in the developing pre-implantation embryo. Finally, by assembling  
90 bovine XENs generated in this study with expanded potential stem cells (EPSCs) (22) and  
91 trophoblast stem cells (TSCs) (23), we generated an improved self-organized bovine blastocyst-  
92 like structure (blastoid) that is more resemble blastocyst compared to the two lineage (ESC and  
93 TSC) assembled blastoids (24).

94

95

## 96 **Results**

### 97 **De novo derivation of bovine XENs from blastocysts**

98 We have previously shown that a combination of four molecules (FGF2, Activin-A, LIF,  
99 and Chir99021) was able to efficiently convert SOX2<sup>+</sup> extended pluripotent stem cells (EPSCs)  
100 into SOX17<sup>+</sup> hypoblast cells in bovine (24). Therefore, we first adapted these four factors (4F-  
101 XENM) to derive bovine XENs from day 8 hatched IVF blastocysts. We observed XEN-like  
102 colonies' outgrowth (Fig. S1A). Since robust hypoblast markers remain largely unknown in  
103 bovine, by mining a single cell RNA-seq dataset of bovine day 12 embryo (7), we identified a  
104 group of novel bovine hypoblast marker genes including CTSV, FETUB, APOA1, APOE,  
105 COL4A1, and FN1 (**Fig. S1B, C**). We found that these bXEN-like cells highly expressed all  
106 identified bovine hypoblast markers, while barely expressed epiblast (SOX2, OCT4, and  
107 NANOG) or trophoblast (CDX2, GATA3, and GATA2) markers (**Fig. S1D**). However, these XENs  
108 can only be maintained up to ten passages, therefore, named as short-term passaged bovine  
109 XENs, or bXEN<sup>S</sup>.

110 Recently, human authentic hypoblast cells were successfully induced from naïve  
111 pluripotent stem cells with seven chemical molecules, including BMPs (a pSMAD1/5/9 activator),  
112 IL-6 (a pSTAT3 activator), FGF4, A83-01 (a pSMAD2 inhibitor and ALK4/5/7 inhibitor) and  
113 XAV939 (a WNT/ $\beta$ -catenin inhibitor and tankyrase inhibitor) along with PDGF-AA and retinoic  
114 acid (19). To further establish long-term culture of bovine XENs, we assessed the different  
115 combinations of these seven factors with the 4F-XENM. Our comprehensive screening process  
116 showed that neither seven factors nor adding individual or any combinations of seven factors  
117 into 4F-XENM medium could establish stable bovine XENs (**Table. S1**). Surprisingly, we found  
118 that a combination of FGF4, BMP4, IL-6, XAV939, and A83-01 (5F-XENM) was able to  
119 efficiently support the outgrowth of bXEN-like morphological colonies from blastocysts (**Fig. 1A**).

120 The derived bXENs-like colonies maintained stable and self-renewal properties with long-term  
121 passages (>30) (**Fig. 1A**), therefore named as long-term passaged bovine XENs, or bXENs.  
122 Further characterization revealed that bXENs maintained stable epithelial morphology of  
123 flattened colonies with clearly defined margins (**Fig. 1A**) and a normal diploid number of  
124 chromosomes ( $2N = 60$ ) after long-term *in vitro* culture (**Fig. 1B**). Immunostaining analysis  
125 showed that, similar to hypoblasts of bovine blastocysts, bXENs expressed SOX17 and GATA6,  
126 but not either SOX2 or CDX2 which is positive in bEPSCs or bTSCs, respectively (**Fig. 1C, D**).  
127 They also highly expressed all identified novel hypoblast markers (**Fig. 1E**).

128 Furthermore, we determined the essential small molecules that are required for the  
129 maintenance of bXENs. First, A83-01 alone could maintain the stable expansion of bXENs while  
130 the cell proliferation and the marker gene expression were reduced (**Fig. 1F, G, H**). Withdrawal  
131 of A83-01 from 5F-XENM, bXENs exhibited differentiation and failed to expand into stable cell  
132 lines (**Fig. 1I**), suggesting A83-01 is indispensable in maintaining bXENs. Second, we observed  
133 that withdrawal of XAV939 or XAV939 together with IL-6 has a limited impact on the expression  
134 of bXENs' marker genes (**Fig. 1G**) and cell proliferation (**Fig. 1H**). Third, absent of XAV939 and  
135 BMP4 resulted in reduced expression level of hypoblast markers such as FETUB, APOE, and  
136 FN1 (**Fig. 1G**). Finally, we demonstrated that BMP4 and FGF4 were two major factors affecting  
137 bXENs' proliferation (**Fig. 1H**). Together, we demonstrated that 5F-XENM was effective in  
138 supporting the maintenance of bXENs.

139 Collectively, we developed a bovine XENs culture condition supports de novo derivation  
140 and self-renewal of stable bXENs *in vitro*.

141

## 142 **Transcriptional and chromatin accessibility features of bXENs**

143 We next explored the transcriptomes of bXENs by RNA sequencing (RNA-seq) analysis.  
144 We compared the transcriptomes of bXENs with bovine EPSCs (22) and bovine TSCs (25).  
145 Principal component analysis (PCA) revealed that bXENs were clustered distinct from bEPSCs  
146 in PC1 and bTSCs in PC2, respectively (**Fig. 2A**), indicating the unique identity of three types of  
147 bovine stem cells, which is also shown in the correlation analysis (**Fig. S2A**). The identity of  
148 bXENs was further confirmed by the expression of representative marker genes of their  
149 corresponding blastocyst lineages (PrE, Epi, and TE) in these three types of bovine stem cells  
150 (**Fig. 2B**). Of note, bXENs also highly expressed both extraembryonic visceral endoderm (VE)  
151 and parietal endoderm (PE) markers (**Fig. 2B**), suggesting their developmental capacity  
152 towards VE and PE of the yolk sac. Additionally, we identified signaling pathways that were  
153 uniquely enriched in bXENs, including PI3K-Akt, cholesterol metabolism, focal adhesion, TNF,  
154 and TGF-beta signaling pathways (**Fig. 2C**). Intriguingly, when integrating transcriptomes of  
155 bXENs with single cell transcriptomes of hypoblast lineages of bovine peri-implantation embryos  
156 from day 12 through day 18 (7), we found that bXENs are closely clustered with highly  
157 proliferating hypoblasts from spheroid embryos (D12 and D14) while distinct from more  
158 differentiated hypoblasts of elongated embryos (D16 and D18), suggesting bXENs resemble  
159 early hypoblast populations *in vivo* (**Fig. 2D**).

160 Additional transcriptomic comparisons of XENs and ESCs among cattle (22), human  
161 (19), and mice (26) further confirmed the lineage identity of bXENs (**Fig. 2E**). To further  
162 investigate the unique transcriptomic features of bXENs, we explored XEN specific genes

163 compared to ESC in three mammalian species separately and identified 400 genes that are  
164 commonly enriched in XENs (**Fig. S2B**). These genes were involved in regulating canonical  
165 hypoblast functions, including circulatory system development, cell fate commitment, and  
166 embryo development (**Fig. 2F**). Additionally, 274 genes are uniquely in bovine, mainly  
167 manipulating ligand-receptor interaction, cytokine-cytokine receptor interaction, and steroid  
168 hormone biosynthesis (**Fig. 2F**). It is also noteworthy that bovine and human XENs share more  
169 common genes than those compared to mouse.

170 We also conducted ATAC-seq analysis to characterize the genome-wide chromatin  
171 accessibility of bXENs (**Fig. 2G, H**). Our analysis showed that the chromatin accessibilities of  
172 hypoblast lineage marker genes are consistent with their expression profiles (e.g., *APOE* and  
173 *SOX17*) (**Fig. 2I**). We confirmed that canonical hypoblast transcriptional factors (TFs) binding  
174 motifs are enriched in bXENs, such as *GATA6*, *GATA4*, *SOX17* (**Fig. 2J**). In addition, we  
175 identified several novel bovine hypoblast TFs including *CTCF*, *BATF*, *ATF3*, *FOSL2*, *KLF5*, *KLF3*,  
176 *ELF1*, *JUND*, and *NFY*, and *HLF* (**Fig. 2J**). We further validated these novel hypoblast TFs and  
177 confirmed that their chromatin accessibilities are consistent with their gene expression as well  
178 (**Fig. S2C**). Most of them (*CTCF*, *NFYA*, *NFYC*, *JUND*) were also highly expressed in the  
179 hypoblast cells of a day 12 peri-implantation bovine embryo (**Fig. S2D**).

180 Together, the RNA-seq and ATAC-seq analyses confirmed the molecular identity of  
181 bXENs and shed light on the molecular features during the earliest steps of hypoblast  
182 development in bovine.

183

## 184 **bXENs regulate the development of peri-implantation epiblasts**

185 In cattle, the attachment of blastocysts is preceded by a period of rapid growth and  
186 elongation, when hypoblast lineages present dynamic changes between spheroid (D12 and D14)  
187 and elongated (D16 and D18) embryos, and have intense communication with both epiblast and  
188 trophectoderm lineages (7, 27). Given that both epiblast and hypoblast specify from ICM and  
189 the plasticity of two lineages are largely unknown, here we implemented a 3D co-culture model  
190 with our established robust bXENs to examine whether or how hypoblast regulates the  
191 development of epiblast during bovine embryogenesis. We mixed different ratio of bEPSC:  
192 bXEN cell populations (Group1 (G1): bEPSCs / bXENs = 40/0; Group2 (G2): bEPSCs / bXENs  
193 = 10/30; Group3 (G3): bEPSCs / bXENs = 10/0; and Group4 (G4): bEPSCs / bXENs = 0/40)  
194 (**Fig. 3A-D**). We found that co-cultures in both G1 and G2 can form spherical structures, but not  
195 those from G3 and G4 (**Fig. 3A-D**). Next, we conducted immunofluorescence analysis of SOX2  
196 and GATA6 that are exclusively expressed in bEPSCs and bXENs, respectively. We found that  
197 spherical structures organized from bEPSCs alone in G1 largely remain SOX2 positive with  
198 GATA6 positive cells located at the peripheral region (**Fig. 3E**). Further quantification showed  
199 that aggregates in G1 consisted of three types of structures, including T1) SOX2<sup>-</sup> GATA6<sup>+</sup>, T2)  
200 SOX2<sup>+</sup> GATA6<sup>-</sup>, T3) SOX2<sup>+</sup> GATA6<sup>+</sup> (**Fig. 3E**). These results indicate a loss of pluripotency and  
201 randomly differentiation of EPSCs to hypoblasts-like cells in consistent with previous  
202 observations both in humans (19, 28) and bovine (24). On the contrary, co-culture of bEPSCs  
203 with bXENs in G2 resulted in spherical structures with cleaner and smoother periphery region  
204 compared to those of G1 (**Fig. 3B**), suggesting an improved survival of aggregates. Further  
205 immunostaining analysis showed that all cells in G2 remain SOX2 positive without any detection



206 of GATA6<sup>+</sup> cells (**Fig. 3F**), suggesting that the present of bXENs prevents bEPSCs from  
207 differentiation. To rule out the possibility that XENs transdifferentiate into SOX2<sup>+</sup> cells, we  
208 tagged bXENs with GFP, followed by co-culture. We observed that bXENs were aggregated with  
209 bEPSCs on day 1, and all GFP<sup>+</sup> bXENs disappeared by day 4 (**Fig. 3G**). Additionally, we found  
210 that, at the present of bXENs in G2, bEPSCs' proliferation was significantly facilitated than those  
211 of G1, based on the size of formed spherical structures (**Fig. 3H**). These results demonstrated  
212 that the presence of bXENs and associated communications support the growth and stemness  
213 of bEPSCs.

214 To further confirm the role of bXENs in promoting epiblast development, we treated  
215 bovine *in vitro* cultured embryos with defined small molecular cocktails sustaining bXENs  
216 (BMP4, FGF4, A83-01, XAV939, IL-6). The treatment was given at different developmental  
217 period before and after major genome activation or hypoblast specification (Experiment 1 (Exp.  
218 1): day 1-8; Experiment 2 (Exp. 2): day 5-8; Experiment 3 (Exp. 3): day 8-12) (**Fig. 4A**). The  
219 subsequent developmental rate and lineage composition and allocation were measured by  
220 immunostaining analysis of epiblast marker SOX2, hypoblast marker SOX17, and  
221 trophoctoderm marker CDX2. When treating embryos with bXEN signaling cocktails from either  
222 day 1-8 (Exp. 1) or day 5-8 (Exp. 2), we found day 8 hatched blastocysts had a significantly  
223 increased SOX2<sup>+</sup> / SOX17<sup>+</sup> cells ratio compared to the control group (**Fig. 4B, C**). We also  
224 noticed that these bXEN small molecules had no impact on early cleavage and trophoblast  
225 differentiation until blastocyst (**Fig. 4D**). However, the blastocyst hatching rate decreased  
226 dramatically presumably due to the issue of lineage specification within ICM (**Fig. 4D**). Further  
227 treating blastocysts with bXEN signaling cocktails during extended culture period from day 8  
228 (Exp. 3), we observed that day 12 embryos had a well-defined and condensed SOX2<sup>+</sup> spot in  
229 the ICM region (**Fig. 4E**), consistent with *in vivo* D12 embryos (**Fig. S3**), while ICM structure  
230 went through degeneration in control group (**Fig. 4E**). When calculating the ratio of SOX2<sup>+</sup> and  
231 SOX17<sup>+</sup> cells, we observed a significantly higher SOX2<sup>+</sup> cells and lower SOX17<sup>+</sup> cells in treated  
232 group compared to control. These results demonstrated that bXEN signaling cocktails could  
233 effectively protect epiblast from differentiation or degeneration.

234 Taking together, our experiments with both co-culture cell model and IVF embryos  
235 demonstrated that hypoblast regulate the development of epiblast in bovine by preventing its  
236 differentiation during bovine peri-implantation (**Fig. 4F**).

237

### 238 **Generation of bovine blastocyst-like structures by self-organization of bXENs, bEPSCs,** 239 **and bTSCs**

240 We have previously reported the successful generation of bovine blastoids by self-  
241 assembly of bEPSCs and bTSCs in tFACL+PD culture condition (24), which providing an  
242 accessible *in vitro* cell model for studying embryogenesis. However, the blastoids assembled by  
243 the two-lineage approach has shown lower proportion of hypoblast lineage compared to IVF  
244 blastocysts, which may limit their developmental capacity. The availability of bXENs prompted  
245 us to develop improved bovine blastoids through 3D assembly of bXENs, bEPSCs and bTSCs.  
246 We first aggregate three bovine stem cell types (bEPSC / bXEN / bTSC = 8:8:16) with the same  
247 culture condition (FGF2, Activin-A, Chir99021, Lif, and PD0325901) we reported (24). We found  
248 that this condition can support the formation of blastoids with high efficiency (46.60% ± 3.80%)

249 within 4 days. The resulted blastoids contains a blastocoele-like cavity, an outer TE-like layer, and  
250 an ICM-like compartment, morphologically equivalent to day 8 blastocysts (**Fig. 5A, D, E**).  
251 However, these blastoids have vanished SOX17<sup>+</sup> hypoblasts compared to day 8 IVF blastocysts  
252 (**Fig. 5A, D**), same as we observed in our two-lineage assembled blastoids (2L-blastoids) (**Fig.**  
253 **5C**) (24).

254 It has been shown that FGF2 could bias the cell fate of ICM towards PrE (24, 29, 30). As  
255 we integrated XENs, the FGF2 is not necessary for the blastoid induction anymore. Also, MEK  
256 inhibitor PD0325901 inhibits hypoblast specification from ICM (29, 31), which might be the  
257 reason for the vanished hypoblasts. Therefore, we withdrawn both FGF2 and PD0325901 from  
258 the culture condition, and found that the modified medium, ACL (Activin-A, Chir99021, Lif)  
259 supported the formation of blastoids morphologically resemble day 8 IVF blastocysts (**Fig. 5B**).  
260 With this approach (3L-blastoids), the blastoid formation efficiency reached 40.84%  $\pm$  4.76%  
261 within 4 days. Importantly, 3L-blastoids had a similar proportion of hypoblast and a slightly  
262 higher ratio of epiblast population compared to day 8 blastocysts, with majority hypoblast cells  
263 surrounding epiblasts (**Fig. 5B, D**). Additionally, the blastocelle size and ICM/blastocelle ratio of  
264 3L-blastoid were also equivalent to day-8 IVF blastocysts (**Fig. 5F, G**). Thus, the bovine blastoid  
265 established in this study were more closely resembled blastocysts compared to the 2L-blastoids  
266 (24).

267 To determine the transcriptional states of 3L-blastoids, we performed single-nucleus  
268 RNA sequencing (snRNAseq) analysis of 3L-blastoids using the 10x genomics low throughput  
269 (up to 1,000 cells) platform. To ensure the precisely comparison, we generate the first snRNA-  
270 seq dataset of bovine day 8 IVF blastocysts using the same 10x genomics platform. Joint  
271 uniform manifold approximation and projection (UMAP) analysis revealed overall cells from 3L-  
272 blastoid clustered well with blastocyst-derived cells (**Fig. 5H**). We annotated three major cell  
273 clusters from blastocysts representing three blastocyst lineages, including Cluster 1 highly  
274 expressed SOX2, VIM, SLIT2, NNAT, CDH2, and NANOG as epiblasts, Cluster 2 highly  
275 expressed GATA6, HDAC1, HDAC8, HNF4A, PDGFRA, and RUNX1 as hypoblast, and Cluster  
276 3 highly expressed DAB2, GATA2/3, KRT8, SFN, TEAD4, TFAP2C as trophoctoderm cells (**Fig.**  
277 **5I, J**). Of note, in the blastocyst, the defined epiblast cells still expressed hypoblast markers,  
278 and vice versa (**Fig. 5J**), suggesting the segregation of epiblast and hypoblast within ICM has  
279 not completed yet (32). The marker gene expression had the same patterns in all three  
280 annotated lineages from both 3L-blastoids and blastocysts, such as GATA2 (TE markers),  
281 PDGFRA (HYPO markers), and SLIT2 (EPI markers), indicating 3L-blastoid transcriptionally  
282 resemble to blastocyst (**Fig. S4A**). The comparative clustering analysis of blastoid and  
283 blastocyst cells showed that blastoids have a lower hypoblast cell population and higher epiblast  
284 population compared to the blastocysts (**Fig. 5K**). This confounding factor in single cell gene  
285 expression analysis may constitute the difference of lineage composition from immunostaining  
286 analysis. Additionally, we performed GO analysis of genes specifically enriched in each of three  
287 lineages of blastoids. We found genes specific to epiblast involve in regulating nervous system  
288 development, cell junction organization, and stem cell population maintenance, genes  
289 upregulated in hypoblast regulate cell morphogenesis and cell fate commitment, and finally  
290 genes highly expressed in trophoctoderm involve in manipulating lipid biosynthetic process,  
291 actin cytoskeleton organization, and cell migration (**Fig. S4B**). Intriguingly, it was shown that  
292 most of the lineage specific genes in epiblast and hypoblast lineages were transcription factors

293 (TFs) or TF cofactors, unveiling the lineage specific functions of those critical TFs during lineage  
294 specification within ICM and the further differential events (**Fig. S4B**).

295 Together, we developed an efficient and robust protocol to generate bovine blastoids by  
296 assembling bXENs, bEPSCs, and bTSCs that can self-organize and faithfully recreate all  
297 blastocyst lineages.

298

299

## 300 Discussion

301 Hypoblast and its derivatives play a vital role in supporting and patterning the embryo  
302 (33), however, owing to applicable approaches associated with *in vivo* experiments, knowledge  
303 of hypoblast lineage segregation and development remains largely unknown. Here we  
304 demonstrated that a chemical cocktail (FGF4, BMP4, IL-6, XAV939, and A83-01) could support  
305 *de novo* derivation and maintenance of stable bXENs from bovine IVF blastocysts. Hypoblast  
306 lineage segregation and development is a conserved process, while signaling to specify and  
307 sustain hypoblast is divergence among mammalian species. In mice, XENs do not require FGF  
308 signaling and can be maintained in the presence of retinoic acid and Activin-A (17). In humans,  
309 hypoblast induction requires FGF signaling (18) and can also be induced from naïve pluripotent  
310 stem cells using a chemical cocktail (BMPs, IL-6, FGF4, A83-01, XAV939, PDGF-AA, and  
311 retinoic acid) (19). In the domestic species, porcine XENs can be derived from blastocysts using  
312 either LIF/FGF2 or LCDM (LIF, CHIR99021, (S)-(+)-dimethindene maleate, and minocycline  
313 hydrochloride) (13, 14). Of note, LCDM is reported to maintain both bovine iPSCs (34) and  
314 TSCs (25). Interestingly, previous studies have demonstrated that FGF2 is also a key factor  
315 maintaining bovine primitive endoderm cell cells (6, 21). In the presence of FGF2, bEPSCs  
316 could also efficiently produce XENs (24). Here we have also shown that bXENs cells can be  
317 induced in the presence of FGF2, however, they are only capable for short-term self-renewal.  
318 Instead, a modification of human hypoblast induction condition by removing retinoic acid  
319 supports long-term culture of bXENs. The bXENs established in this study fill a gap and add a  
320 reliable stem cell model for research into pre- and peri-implantation development of an ungulate  
321 species.

322 In this study, we have demonstrated the regulatory role of hypoblast in regulating  
323 epiblast development in a ruminant species. This has also been most recently highlighted in  
324 both mouse and humans using *in vitro* experimental models (19, 28, 35). In humans, the  
325 existence of hypoblast can facilitate ESCs in generating a pro-amniotic-like cavity, which  
326 recapitulates the anterior-posterior pattern and mimics several aspects of the post-implantation  
327 embryo (19, 28). In mouse, primitive endoderm stem cells supported the lineage plasticity and  
328 the PrE alone was sufficient to regenerate a complete blastocyst and continue post-implantation  
329 development. Unlike many other mammalian species, ruminant species undergo a unique  
330 conceptus elongation process before implantation. During this phase, dramatic proliferation and  
331 differentiation of trophoblast and hypoblast lineage occur while the germ layer differentiation  
332 from epiblast is only observed until day 16 (7), which may constitute limited developmental  
333 potential of bovine XENs compared to humans and mouse. Thus, the bovine XENs model  
334 established here have mirrored the physiological lineage interaction between hypoblast and  
335 epiblast during bovine conceptus elongation.



336 A final contribution of this study is the development of an improved protocol to assemble  
337 bovine blastoids by self-organization of bXENs, bEPSCs, and bTSCs. In our previous study, the  
338 2 lineages (EPSC and TSC) assembled bovine blastoids had a lower proportion of hypoblast  
339 lineages compared to the IVF blastocysts (24), which may compromise their developmental  
340 potential. Instead, with the integration of bXENs, we have shown that the 3L-blastoids  
341 established here more closely resemble bovine blastocysts compared to the first generation of  
342 bovine blastoids in terms of morphology, lineage composition and allocation, and transcriptional  
343 features. So far, most of the established blastoid models from other species, especially human,  
344 are self-organized from naïve ESCs or EPSCs (36-38), which comes up with concern that the  
345 differentiated TE-like lineage is transcriptionally resemble to amniotic ectoderm (39). By utilizing  
346 the assembly approach with authentic TSCs could eliminate this concern. Strikingly, embryo-like  
347 structures were generated through assembling mouse ESCs, TSCs, and XENs *in vitro*, which  
348 recapitulates the developmental characteristics of mouse embryos up to day 8.5 (40, 41),  
349 demonstrating that blastoids derived by assembling approach with three lineages possess  
350 higher developmental potential. This is significant in large mammals, particularly for the  
351 domestic species, as blastoid technology established here, upon further optimization and *in vivo*  
352 function testing, could lead to the development of novel artificial reproductive technologies for  
353 cattle breeding, which may enable a paradigm shift in livestock reproduction.

354 In summary, our work has established an authentic extraembryonic endoderm cell line  
355 and developed an improved bovine blastoid technology. We have also shown the valuable of  
356 bovine XEN in modeling cell-cell communications, thus filling a significant knowledge gap in the  
357 study of bovine embryogenesis when most of pregnancy failure occurs.

358 **METHODS**

359 **Key resources table**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
Anti- SOX17	R&D SYSTEMS	Cat. No. AF1924
Anti- GATA6	R&D SYSTEMS	Cat. No. AF1700
Anti- SOX2	Biogenex	Cat. No. AN833
Anti- CDX2	Biogenex	Cat. No. AM3920324
Alexa Fluor 647 anti-rabbit antibody	Invitrogen	Cat. No. A31573
Alexa Fluor 555 anti-mouse antibody	Invitrogen	Cat. No. A31570
Alexa Fluor 488 anti-goat antibody	Invitrogen	Cat. No. A32814
<b>Chemicals, peptides, and recombinant proteins</b>		
Recombinant human LIF	Peprotech	Cat. No. 300-05
CHIR99021	Sigma	Cat. No. SML-1046
Dimethinedene maleate	Tocris	Cat. No. 14-251-0
Minocycline hydrochloride	Santa cruz	Cat. No. sc-203339
Insulin-Transferrin-Selenium- Ethanolamine (ITS-X)	Gibco	Cat. No. 51500056
PD0325901	Axon Medchem	Cat. No. 1408
Recombinant Human FGF-basic	Peprotech	Cat. No. 100-18B
Recombinant Human/Murine/Rat Activin A	Prepotech	Cat. No. 120-14p
Emricasan	Selleckchem	Cat. No. 50-136-5234
Polyamine supplement 5ml	Sigma	Cat. No. P8483
trans-ISRIB,10mg	Tocris	Cat. No. 5284
Chroman 1 (HY15392), 5mg	Medchemexpress	Cat. No. 502029121
mTeSR™ 1	STEMCELL	Cat. No. 85850
WH-4-023	Tocris	Cat. No. 5413
endo-IWR 1	Sigma	Cat. No. I0161
XAV-939	Sigma	Cat. No. X3004
L-Ascorbic acid 2-phosphate	Sigma	Cat. No. A92902
FGF4	sigma	Cat. No. F8424
BMP4	R&D SYSTEMS	Cat. No. 314-BP-050/CF
IL-6	Sigma	Cat. No. SRP3096
A83-01	Sigma	Cat. No. SML0788
Knockout™ SR	Gibco	Cat. No. 10828-028
PDGF	R&D SYSTEMS	Cat. No. BT220-010/CF
DMEM	Gibco	Cat. No. 11995-040
FBS	Gibco	Cat. No. 26140-079
Dulbecco's phosphate buffered saline (1X), no calcium, no magnesium (DPBS)	Sigma	Cat. No. D8537
Y-27632	Tocris	Cat. No. 1254

DMEM/F12 medium	HyClone	Cat. No. SH30023.01
Neurobasal medium	Gibco	Cat. No. 21103-049
N2 supplement (100X)	Gibco	Cat. No. 17502-048
B27 supplement (50X)	Gibco	Cat. No. 17504044
MEM Non-Essential Amino Acids Solution (100X)	Gibco	Cat. No. 11140-050
GlutaMAX™ Supplement (100X)	Gibco	Cat. No. 35050061
2-Mercaptoethanol (55mM)	Gibco	Cat. No. 21985023
Accutase	Gibco	Cat. No. A1110501
Tn5 transposase	illumina	Cat. No. 20034197
BSA	MP Biomedicals	Cat. No. 0219989950
TrypLE_ Express	Gibco	Cat. No. 12605-010
<b>Critical commercial assays</b>		
KaryoMax colcemid solution	Gibco	Cat. No. 15212012
Feeder removal MicroBeads, mouse	Miltenybiotec	Cat. No. 130-095-531
<b>Deposited data</b>		
bXENs RNAseq, ATACseq	This paper	GEO:
bTSCs RNAseq	Wang et al. (25)	GEO: GSE220923
bEPSCs RNAseq	Zhao et al. (22)	GEO: GSE129760
D12-D18 elongation scRNAseq	Scatolin et al. (7)	GEO: GSE234335
hXENs, hNESCs, hPESCs RNAseq	Okubo et al. (19)	GEO: GSE131747
mXENs, mESCs RNAseq	Zhong et al. (26)	GEO: GSE106158
Blastocyst snRNAseq	This paper	GEO:
3L-Blastoid snRNAseq	This paper	GEO:
<b>Software and algorithms</b>		
CellRanger (v.7.1.0)	10x Genomics	<a href="https://support.10xgenomics.com/single-cellgene-expression/software/pipelines/latest/what-is-cell-ranger">https://support.10xgenomics.com/single-cellgene-expression/software/pipelines/latest/what-is-cell-ranger</a>
Seurat (v.4.3.0)	Satija et al. (42)	<a href="https://github.com/satijalab/seurat">https://github.com/satijalab/seurat</a>
SCP (v.0.4.0)	N/A	<a href="https://github.com/zhanghao-njmu/SCP">https://github.com/zhanghao-njmu/SCP</a>
clusterProfiler (v.4.6.1)	Yu et al. (43)	<a href="https://bioconductor.org/packages/release/bioc/html/clusterProfiler.html">https://bioconductor.org/packages/release/bioc/html/clusterProfiler.html</a>
HISAT2 (v.2.2.1)	Kim et al. (44)	<a href="http://daehwankimlab.github.io/hisat2/">http://daehwankimlab.github.io/hisat2/</a>

EdgeR (v.4.2.1)	Robinson et al. (45)	<a href="https://bioconductor.org/packages/release/bioc/html/edgeR.html">https://bioconductor.org/packages/release/bioc/html/edgeR.html</a>
bowtie2 (v. 2.5.1)	Langmead and Salzberg (46)	<a href="https://bowtie-bio.sourceforge.net/bowtie2/index.shtml">https://bowtie-bio.sourceforge.net/bowtie2/index.shtml</a>
IGV	Robinson et al. (47)	<a href="https://software.broadinstitute.org/software/igv/">https://software.broadinstitute.org/software/igv/</a>
HOMER	Heinz et al. (48)	<a href="http://homer.ucsd.edu/homer/motif/">http://homer.ucsd.edu/homer/motif/</a>
Trim Galore (v.0.6.7)	N/A	<a href="http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/">http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/</a>
featureCounts (v.2.0.1)	Liao et al. (49)	<a href="https://subread.sourceforge.net/featureCounts.html">https://subread.sourceforge.net/featureCounts.html</a>
MACS2 (v. 2.2.9.1)	Zhang et al. (50)	<a href="https://pypi.org/project/MACS2/">https://pypi.org/project/MACS2/</a>
SAMtools (v.1.17)	Danecek et al. (51)	<a href="https://github.com/samtools/samtools">https://github.com/samtools/samtools</a>
Other		
AggreWell 400	STEMCELL	Cat. No. 34415
Anti-Adherence Rinsing	STEMCELL	Cat. No. 07010
CELLBANKER 1	AMSBIO	Cat. No. 11910
CELLBANKER 2	AMSBIO	Cat. No. 11914
Smart-seq2 v4 kit	Takara Bio	Cat. No. 634897
Nextera XT DNA Library Preparation Kit	illumina	Cat. No. 15032350
Nextera XT Indexes	illumina	Cat. No. 15052163
Chromium Controller & Next GEM Accessory Kit	10X Genomics	Cat. No. 000204
Chromium Nuclei Isolation Kit	10X Genomics	Cat. No. PN-1000494
Chromium Next GEM Chip G Single Cell Kit	10X Genomics	Cat. No. 1000127
Chromium Next GEM Single Cell 3' Kit v3.1	10X Genomics	Cat. No. 1000269

360

### 361 RESOURCE AVAILABILITY

362 **Lead contact:** Further information for resources and reagents should be directed to the lead  
 363 contact, Zongliang Jiang ([z.jiang1@ufl.edu](mailto:z.jiang1@ufl.edu)).

364 **Materials availability:** This study did not generate new unique reagents.

## 365 **Data and code availability**

- 366 • The raw FASTQ files and normalized read accounts per gene are available at Gene  
367 Expression Omnibus (GEO) (<https://www.ncbi.nlm.nih.gov/geo/>) under the accession  
368 number GSE283042 and GSE283048. This paper analyzes publicly available data. The  
369 accession numbers for the datasets are listed in the key resources table.
- 370 • This paper does not report original code.
- 371 • Any additional information required to reanalyze the data reported in this paper is  
372 available from the lead contact upon request.

373

## 374 **METHOD DETAILS**

### 375 **Bovine IVF embryo production**

376 The IVF embryos used in this study were produced as previously described (52). Briefly,  
377 bovine cumulus-oocyte complexes (COCs) were aspirated from selected follicles of  
378 slaughterhouse ovaries. BO-IVM medium (IVF Bioscience) was used for oocyte *in vitro*  
379 maturation. IVF was performed using cryopreserved semen from a Holstein bull with proven  
380 fertility. Embryos were then washed and cultured in BO-IVC medium (IVF Bioscience) at 38.5 °C  
381 with 6% CO<sub>2</sub>. Day 8 hatched blastocysts were collected and were processed for bXENS  
382 derivation. For post-hatching culture from day8 until day12, embryos were transferred into  
383 extended culture medium containing DMEM: F12 (Gibco) and Neurobasal medium (Gibco) (1:1),  
384 1x N2-supplement (Gibco), 1x B27-supplement (Gibco), 1x NEAA (Gibco), 1x GlutaMAX (Gibco),  
385 0.1 mM 2-mercaptoethanol (Gibco), 10 µM/mL ROCK inhibitor (Tocris, 1254), 20 ng/mL ActivinA  
386 (Peprotech, 100-18B). For the treatment group, 25 ng/mL FGF4 (sigma, F8424), 10 ng/mL  
387 BMP4 (R&D SYSTEMS, 314-BP-050/CF), 1µM XAV939 (sigma, X3004-5MG), 3µM A83-01  
388 (sigma SML0788-25MG), 10ng/mL IL-6 (sigma, SRP3096) were added.

389

### 390 **Derivation and culture of bXENS**

391 ICMs were isolated from day 8 blastocysts by microsurgery and were placed in separate  
392 wells of a 24-well plate that was seeded with mitomycin C-treated mouse embryonic fibroblast  
393 (MEF) cells. To derive bXEN<sup>S</sup>, the ICMs were initially cultured in pre-bXENM<sup>S</sup> containing DMEM:  
394 F12 and Neurobasal medium (1:1), 1x N2-supplement, 1x B27-supplement, 1x NEAA, 1x  
395 GlutaMAX, 0.1 mM 2-mercaptoethanol, 20 ng/mL bFGF (Peprotech, 100-18B), 20 ng/mL  
396 ActivinA. After three days, when all the ICMs attach and form outgrowth, change the medium to  
397 bXENM<sup>S</sup> containing DMEM: F12 and Neurobasal medium (1:1), 0.5x N2-supplement, 0.5x B27-  
398 supplement, 0.5x NEAA, 0.5x GlutaMAX, 0.1 mM 2-mercaptoethanol, 1mM NaPy (Sigma,  
399 s8636), 10 µg/ml l-ascorbic acid (Sigma, A92902), 1x ITS-X (Gibco, 51500-056), 0.1% FBS, 0.5%  
400 KSR, 20 ng/mL LIF (Peprotech, 300-05), 1µM Chir99021 (Sigma, SML-1046), 10 ng/mL bFGF,  
401 10 ng/mL ActivinA.

402 To derive bXEN, the ICMs were cultured in 5F-XENM containing DMEM: F12 and  
403 Neurobasal medium (1:1), 1x N2-supplement, 1x B27-supplement, 1x NEAA, 1x GlutaMAX, 0.1  
404 mM 2-mercaptoethanol, 25 ng/mL FGF4, 10 ng/mL BMP4, 1µM XAV939, 3µM A83-01, 10ng/mL  
405 IL-6. To promote the proliferation of hypoblast, 0.1% KSR, 0.1% BSA (MP biomedical),



406 20ng/mL ActivinA, and 10 ng/mL PDGF (R&D SYSTEMS, BT220-010/CF) were also added  
407 during the derivation of bXEN and were optional for bXENs maintenance. All the cells were  
408 cultured at 38.5°C and 5% CO<sub>2</sub>. The culture medium was changed every other day. On day 7 or  
409 8, outgrowths were dissociated by TrypLE (Gibco, 12605-010) for 5-7 mins at 38.5 °C and  
410 passaged. For optimal survival rate, 10 μM Rho-associated protein kinase (ROCK) inhibitor Y-  
411 27632 was added to the culture medium during first 24 hours. Once established, both bXEN<sup>S</sup>  
412 and bXEN were passaged every 3-5 days at a 1:5 split ratio using TrypLE. Each well of cells  
413 was dissociated by 0.5mL TrypLE for 5 mins at 38.5°C, the same volume of DMEM/F12 with 1%  
414 BSA was used to neutralize. bXENs could be cryopreserved by CELLBANKER 2 (ZENOGEN)  
415 according to the manufacturer's instructions.

416

### 417 **Bovine EPSCs culture**

418 Bovine EPSCs were maintained in bovine EPSC culture medium (3i+LAF) (22): mTeSR  
419 base (STEMCELL, 85850), 1% BSA, 10ng/ml LIF, 20ng/ml Activin A, 0.3 μM WH-4-023, 1 μM  
420 Chir99021, 5 μM IWRI, 50 μg/ml Ascorbic acid (Vitamin C). bEPSCs were passaged every 2  
421 days at a 1:6 split ratio using TrypLE. Each well of cells was dissociated by 0.5mL TrypLE for 5  
422 mins at 38.5°C, the same volume of bXEN medium was used to neutralize TrypLE, ROCK  
423 inhibitor is necessary for each passage. bEPSCs could be cryopreserved by CELLBANKER 2  
424 according to the manufacturer's instructions.

425

### 426 **Bovine TSCs culture**

427 Bovine TSCs were derived and cultured in LCDM (25) (hLIF, CHIR99021, DiM and MiH)  
428 media (DMEM: F12 and Neurobasal medium (1:1), 0.5x N2-supplement, 0.5x B27-supplement,  
429 1x NEAA, 1x GlutaMAX, 0.1 mM 2-mercaptoethanol, 0.1% BSA (MP biomedical), 10 ng/mL LIF,  
430 3 μM CHIR99021, 2 μM Dimethinedene maleate (DiM) (Tocris, 1425) and 2 μM Minocycline  
431 hydrochloride (MiH) (Santa cruz, sc-203339). bTSCs were passaged every 4 days at a 1:4 split  
432 ratio using Accutase (Gibco, A1110501). Each well of bTSCs was dissociated by 1mL Accutase  
433 for 5 mins at 38.5°C, the same volume of bTSCs medium was used to dilute Accutase for  
434 neutralizing the reaction. bTSCs were cryopreserved by CELLBANKER 1 according to the  
435 manufacturer's instructions.

436

### 437 **Generation of reporter bXENs**

438 The pLenti CMV GFP Puro plasmid (Addgene #17448) was packaged into lentivirus in  
439 293T cells using JetPrime reagent (Polyplus, 101000015) following manufacturer's instructions.  
440 After 48 hours incubation, the medium was collected and concentrated using the Lenti-X™  
441 Concentrator (Takara, 631231). Then the GFP-lentiviruses were transfected into bXENs with  
442 5μg/ml polybrene (sigma, TR-1003-G). 1μg/mL of puromycin (sigma, P8833) was added to the  
443 culture medium 2–3 days after transfection. Drug-resistant colonies with GFP signaling were  
444 manually picked and further expanded.

445

## 446 **Blastoid formation**

447 For 3L-blastoid formation, bEPSCs, bTSCs, and bXENs were dissociated into single  
448 cells by treating with TrypLE for 3min, 15min, and 7min, respectively, followed by neutralizing  
449 with the same volume of their culture medium. After centrifugation at 300 x g for 5min, cells  
450 were resuspended in their normal culture media with ROCK inhibitor. Single-cell dissociation  
451 was made by gentle but constant pipetting until no visible cell clumps exist. To deplete iMEF  
452 cells, cells of three cell lines were filtered through passing 40mm cell strainers (Corning)  
453 separately and placed in precoated 6 well plates (Corning) with 0.1% gelatin and incubated for  
454 35 minutes at 38.5 °C. Cells were then collected and stained with 1x trypan blue and manually  
455 counted in a Neubauer chamber. Current protocol is optimized for 8 bEPSCs, 8 bXENs and 16  
456 bTSCs per well in a 1200 well Aggrewell 400 microwell culture plate (Stemcell technologies) for  
457 9,600, 9,600, and 19,200 of each cell type per well. Each well was precoated with 500ml of Anti-  
458 Adherence Rinsing Solution (Stemcell technologies) and spun for 5 minutes at 1500 x g. Wells  
459 were rinsed with 1ml of PBS just before aggregation. The cells for one well were mixed and  
460 centrifuged at 300 x g for 5min, followed by resuspension with 1mL ACL medium (DMEM: F12  
461 and Neurobasal medium (1:1), 1x N2-supplement, 1x B27-supplement, 1x NEAA, 1x GlutaMAX,  
462 0.1 mM 2-mercaptoethanol, 0.5x ITS-X, 20 ng/ml LIF, 10 ng/ml ActivinA, 1µM Chir99021,  
463 supplemented with 1x CEPT cocktail (53) (50 nM chroman-1 (C, Tocris), 5 µM emricasan (E,  
464 Selleckchem), 0.7 µM trans-ISRIB (T, Tocris), and 1 x polyamine supplement (P, Thermo)). To  
465 ensure even distribution of the cells within each microwell, cells were gently mixed by pipetting  
466 with a P200 pipette. The plate was first placed in incubator for 8 min to allow the cells to settle  
467 down, then centrifuged at 700 x g for 3 minutes and put back to incubator. Half of the medium  
468 was changed daily, the blastoids showed up from day 2 and could be collected on day 3 or day4.

469

## 470 **Bovine EPSCs and XENs aggregation assay**

471 bEPSCs, and bXENs were dissociated into single cells and depleted feeder cells as  
472 described above. Ten bEPSCs and 30 bXENs, or 40 bEPSCs, or 10 bEPSCs, or 40 bXENs  
473 seeded in each well of a 1200 well Aggrewell 400 microwell culture plate under N2B27 medium  
474 (DMEM: F12 and Neurobasal medium (1:1), 1x N2-supplement, 1x B27-supplement, 1x NEAA,  
475 1x GlutaMAX, 0.1 mM 2-mercaptoethanol) with 5% KSR and 10 µM Y27632. Half of the medium  
476 was changed daily and the aggregation structures were cultured until day 4.

477

## 478 **Karyotyping assay**

479 bXENs were incubated with 1 mL KaryoMAX colcemid solution (Gibco, 15212012) at  
480 38.5°C for 4-5 hours. Cells were then dissociated using 1 mL Trypsin (Gibco, 25200-056) at  
481 38.5°C and centrifuged at 300 x g for 5 min. The cells were resuspended in 1mL PBS solution  
482 and centrifuged at 400 x g for 2 min. The supernatant was aspirated and 500 mL 0.56% KCl  
483 was added to resuspend the cells. The cells were incubated for 15 min, then centrifuged at 400  
484 x g for 2 min. 1 mL cold fresh Carnoy's fixative (3:1 methanol: acetic acid) was added to  
485 resuspend the cells, followed by a 10 min incubation on ice. After centrifuge, 200 mL Carnoy's  
486 fixative was added to resuspend the cells. Cells were dropped on the clean slides and air dried  
487 and soaked in a solution (1:25 of Giemsa stain (Sigma, GS500): deionized water) for 9 min.

488 Slides were rinsed with deionized water and air dried. The images were taken by Leica DM6B at  
489 1000x magnification under oil immersion.

490

### 491 **Immunofluorescence analysis**

492 Cells, blastoids, and blastocysts were fixed in 4% paraformaldehyde (PFA) for 20 min at  
493 room temperature, and then rinsed in wash buffer (0.1% Triton X-100 and 0.1% polyvinyl  
494 pyrrolidone in PBS) three times. Following fixation, cells were permeabilized with 1% Triton X-  
495 100 in PBS for 30 min and then rinsed with wash buffer. Samples were then transferred to  
496 blocking buffer (0.1% Triton X-100, 1% BSA, 0.1 M glycine, 10% donkey serum) for 2 hours at  
497 room temperature. Subsequently, the cells were incubated with the primary antibodies overnight  
498 at 4°C. The primary antibodies used in this experiment include anti-SOX2 (Biogenex, an833),  
499 anti-CDX2 (Biogenex, MU392A; 1:100), anti-GATA6 (R&D SYSTEMS, AF1700; 1:100), and anti-  
500 SOX17 (R&D SYSTEMS, AF1924; 1:100). For secondary antibody incubation, the cells were  
501 incubated with Fluor 488- or 555- or 647-conjugated secondary antibodies for 1 hour at room  
502 temperature. Followed by DAPI staining (Invitrogen, D1306) for 15 min. The images were taken  
503 with a fluorescence confocal microscope (Leica).

504

### 505 **Quantitative real-time PCR**

506 Total RNA was extracted from cells using RNeasy Micro Kit (Qiagen) according to the  
507 manufacture's protocol. First-strand cDNA was synthesized using the iScript cDNA Synthesis Kit  
508 (BIO-RAD). The qRT-PCR was performed using SYBR Green PCR Master Mix (BIORAD) with  
509 specific primers (**Table. S2**). Data was analyzed using the BIO-RAD software provided with the  
510 instrument. The relative gene expression values were calculated using the  $\Delta\Delta\text{CT}$  method and  
511 normalized to internal control beta-actin.

512

### 513 **RNA-seq library preparation and data analysis**

514 Total RNA of bXENs was extracted using RNeasy Micro Kit (Qiagen). The RNA-seq  
515 libraries were generated using the Smart-seq2 v4 kit with minor modifications from the  
516 manufacturer's instructions. Briefly, individual cells were lysed, and mRNA was captured and  
517 amplified with the Smart-seq2 v4 kit (Clontech). After AMPure XP beads purification, the high-  
518 quality amplified RNAs were subject to library preparation using Nextera XT DNA Library  
519 Preparation Kit (Illumina) and multiplexed by Nextera XT Indexes (Illumina). The concentration  
520 of sequencing libraries was determined using Qubit dsDNA HS Assay Kit (Life Technologies)  
521 and KAPA Library Quantification Kits (KAPA Biosystems). The size of sequencing libraries was  
522 determined using the Agilent D5000 ScreenTape with TapeStation 4200 system (Agilent). Pooled  
523 indexed libraries were then sequenced on the Illumina HiSeq X platform with 150-bp pair-end  
524 reads.

525 Multiplexed sequencing reads that passed filters were trimmed to remove low-quality  
526 reads and adaptors by Trim Galore (version 0.6.7) (-q 25 -length 20 -max\_n 3 -stringency 3).  
527 The quality of reads after filtering was assessed by FastQC, followed by alignment to the bovine

528 genome (ARS-UCD1.3) by HISAT2 (version 2.2.1) with default parameters. The output SAM  
529 files were converted to BAM files and sorted using SAMtools6 (version 1.14). Read counts of all  
530 samples were quantified using featureCounts (version 2.0.1) with the bovine genome as a  
531 reference and were adjusted to provide counts per million (CPM) mapped reads. Principal  
532 component analysis and cluster analysis were performed with R (a free software environment  
533 for statistical computing and graphics). Differentially expressed genes (DEGs) were identified  
534 using edgeR in R. Genes were considered differentially expressed when they provided a false  
535 discovery rate of  $<0.05$  and fold change  $>2$ . ClusterProfiler was used to reveal the Gene  
536 Ontology and KEGG pathways in R.

537

### 538 **ATAC-seq library preparation and data analysis**

539 The ATAC-seq libraries from fresh cells were prepared as previously described (52).  
540 Shortly, cells were lysed on ice, then incubated with the Tn5 transposase (TDE1, Illumina) and  
541 tagmentation buffer. Tagmented DNA was purified using MinElute Reaction Cleanup Kit  
542 (Qiagen). The ATAC-seq libraries were amplified by Illumina TrueSeq primers and multiplexed  
543 by index primers. Finally, high quality indexed libraries were pooled together and sequenced on  
544 Illumina NovaSeq platform with 150-bp paired-end reads.

545 The ATACseq analysis followed our established analysis pipeline (52). All quality  
546 assessed ATAC-seq reads were aligned to the bovine reference genome using Bowtie 2.3 with  
547 following options: `-very-sensitive -X 2000 -no-mixed -no-discordant`. Alignments resulted from  
548 PCR duplicates or locations in mitochondria were excluded. Only unique alignments within each  
549 sample were retained for subsequent analysis. ATAC-seq peaks were called separately for each  
550 sample by MACS2 with following options: `-keep-dup all -nolambda -nomodel`. The ATAC-seq  
551 bigwig files were generated using bamcoverage from deeptools. The ATAC-seq signals were  
552 normalized in the Integrative Genome Viewer genome browser. The enrichment of  
553 transcriptional factor motifs in peaks was evaluated using HOMER  
554 (<http://homer.ucsd.edu/homer/motif/>).

555

### 556 **Single nuclei isolation and library preparation**

557 The snRNA-seq libraries from frozen blastoids and day 8 blastocysts were prepared  
558 using Chromium Nuclei Isolation Kit (10x Genomics, PN-1000493) with minor modifications from  
559 the manufacturer's instructions. In brief, frozen blastoids and day 8 blastocysts were transferred  
560 to pre-chilled sample dissociation tube and were dissociated with pestle within lysis buffer, then  
561 the tube was incubated on ice for 7 min. Then the dissociated sample was pipetted onto  
562 assembled nuclei isolation column and centrifuged 16,000 x rcf for 20 sec. After being washed  
563 with debris removal buffer and wash buffer, the nuclei pellet was resuspended in 50  $\mu$ l  
564 resuspension buffer and performed cell counting. Nucleus were loaded into a 10x Genomics  
565 Chromium Chip following manufacturer instruction (10x Genomics, Chromium Next GEM Single  
566 Cell 3' Reagent Kit v3.1 Dual Index) and sequenced with an Illumina Novaseq 6000 System  
567 (Novogene).

568

## 569 **snRNA-seq data analysis**

570 To analyze 10X Genomics single-cell data, the base call files (BCL) were transferred to  
571 FASTQ files by using CellRanger (v.7.1.0) mkfastq with default parameters, followed by aligning  
572 to the most recent bovine reference genome downloaded from Ensembl database (UCD1.3),  
573 then the doublets were detected and removed from single cells by using Scrublet (0.2.3) with  
574 default parameters. The generated count matrices from all the samples were integrated by R  
575 package Seurat (4.3.0) utilizing canonical correlation analysis (CCA) with default parameters  
576 ([https://satijalab.org/seurat/articles/get\\_started.html](https://satijalab.org/seurat/articles/get_started.html)). The data was scaled for linear dimension  
577 reduction and non-linear reduction using principal component analysis (PCA) and UMAP,  
578 respectively. The following clustering and visualization were performed by using the Seurat  
579 standard workflow with the parameters “dim = 1:10” in “FindNeighbors” function and “resolution  
580 =0.5” in “FindClusters” function. The function “FindAllMarkers” in Seurat was used to identify  
581 differentially expressed genes in each defined cluster. The cutoff value to define the differentially  
582 expressed genes was p.adjust value <0.05, and fold change >0.25. The UMAP plots and bubble  
583 plots with marker genes were generated using “CellDimPlot” and “GroupHeatmap” functions in  
584 R package SCP (0.4.0) (<https://github.com/zhanghao-njmu/SCP>), respectively. Gene ontology  
585 (GO) and pathway analysis were performed using R package clusterProfiler (4.6.1).

586

## 587 **Quantification and statistical analysis**

588 Data were analyzed using GraphPad Prism 9 (GraphPad Software, Inc.) unless  
589 otherwise stated. Two-tailed unpaired or paired *t*-tests were used to determine the significance  
590 of differences between the means of two groups. One-way ANOVA followed by multiple  
591 comparisons was used to determine the significance of differences among means of more than  
592 two groups. Values of  $p < 0.05$  were considered statistically significant. Statistical analyses of  
593 sequencing data were performed in R. Genes with |fold change| >2 and  $p$  value < 0.05 were  
594 identified as significant DEGs. Gene ontology (GO) and pathway analysis were performed using  
595 R package clusterProfiler (4.6.1). The value of  $p$  value < 0.05 was considered significant.



## 596 Figure legends

597 **Figure 1. Derivation and characterization of bXENs.** **A.** Representative image of outgrowth  
598 that formed from day 8 bovine blastocyst contains three morphologically distinct cell types and  
599 subsequent derivation and maintenance of bXENs. **B.** Karyotype analysis of bXENs at passage  
600 15. **C.** Immunofluorescence analysis of GATA6 and SOX17 (hypoblast markers), SOX2 (epiblast  
601 marker), as well as CDX2 (trophectoderm marker) in day 8 blastocysts. Scale bar, 50 $\mu$ m. **D.**  
602 Immunofluorescence analysis of GATA6, SOX17, SOX2, as well as CDX2 in bXENs, bEPSCs,  
603 and bTSCs, separately. Scale bar, 25 $\mu$ m. **E.** Relative expression of defined lineage marker  
604 genes in three stem cell lines. **F.** The small molecules included in each medium recipe (R1-R6).  
605 **J.** Relative expression level of hypoblast marker genes in bXENs cultured in different mediums  
606 from **F.** **H.** Cell number estimated within 3 days following passage. **I.** Morphology of bXENs  
607 cultured in XENM with or without A83-01. Data are presented as the mean  $\pm$  SEM. \* $P < 0.05$   
608 from one-way analysis of variance (ANOVA) followed by Tukey's multiple comparisons test.

609  
610 **Figure 2. Transcriptomic and chromatin accessible features of bovine XENs.** **A.** Principal  
611 component analysis (PCA) of transcriptomes of bXEN, bEPSC<sup>emb</sup>, bEPSC<sup>iPS</sup>, and bTSC. **B.**  
612 Heatmap showing the marker gene expression for PrE, VE, PE, Epi, and TE from each bovine  
613 stem cell type. **C.** Heatmap (left panel) showing lineage-specific expressed genes for bXENs,  
614 bEPSCs, and bTSCs, as well as the enriched signaling pathways (right panel). **D.** PCA of  
615 transcriptomes of bXENs and three major lineages from day 12-18 bovine *in vivo* embryos. **E.**  
616 PCA of transcriptomes of XEN and ESC from bovine, mouse, and human. Datasets of  
617 bEPSC<sup>emb</sup> and bEPSC<sup>iPS</sup> are from Zhao et al., PNAS 2021; Datasets of hNESC<sup>H1</sup>, hNESC<sup>H9</sup>,  
618 hNESC<sup>iPS</sup>, hPESC, hXEN<sup>7F</sup>, and hXEN<sup>GATA6OE</sup> are from Okubo et al., Nature 2024. Datasets of  
619 mESC, mpXEN and mXEN are from Zhong et al., Stem Cell Research 2018. **F.** Venn diagram  
620 (top panel) showing the number of XEN enriched genes when compared to ESC among three  
621 mammalian species, as well as the enriched GO/KEGG (bottom panel) categories from  
622 overlapped genes and bovine specific genes, respectively. **G.** The enrichment of ATACseq  
623 peaks at annotated promoters (TSS  $\pm$  2kb) (normalized and on average) in bXENs. **H.** Feature  
624 distribution of ATACseq peaks in bXENs. **I.** The genome browser views showing the ATAC-seq  
625 peaks and RNA-seq reads enrichment near *APOE* and *SOX17* in bXENs. **F.** Motif enrichment  
626 analysis of ATAC-seq peaks from bXENs.

627  
628 **Figure 3. 3D co-culture of bEPSCs and bXENs.** **A.** Aggregates formed by 40 bEPSC cells  
629 cultured in N2B27 medium with 5% KSR. **B.** Aggregates formed by the mixture of bEPSCs and  
630 bXENs cultured in N2B27 medium with 5% KSR. **C.** Aggregates formed by 10 bEPSC cells  
631 cultured in N2B27 medium with 5% KSR. **D.** Aggregates formed by 40 bXEN cells cultured in  
632 N2B27 medium with 5% KSR. **E.** Immunofluorescence analysis of cell aggregates formed by  
633 bEPSCs. Green, SOX2; Pink, GATA6; Blue, DAPI. **F.** Immunofluorescence analysis of cell  
634 aggregates formed by mixture of bEPSCs and bXENs. Green, SOX2; Pink, GATA6; Blue, DAPI.  
635 **G.** Aggregates generated by the mixture of 10 bEPSCs and 30 GFP tagged bXENs on day1 and  
636 day4, respectively. **H.** Diameters of aggregates formed by the mixture of bEPSCs and bXENs  
637 (E+X) or by the bEPSCs (E) alone. Data are presented as the mean  $\pm$  SEM. \* $P < 0.05$  from  
638 unpaired *t*-test.

639

640 **Figure 4. bXENs regulate the development of peri-implantation epiblasts.** **A.** Schematic  
641 summarizing the treatment. The treatment was given at different developmental period before  
642 and after major genome activation or hypoblast specification (Experiment 1 (Exp. 1): day 1-8;  
643 Experiment 2 (Exp. 2): day 5-8; Experiment 3 (Exp. 3): day 8-12). **B.** Immunofluorescence  
644 analysis of SOX17 (hypoblast marker), SOX2 (epiblast marker), and CDX2 (trophectoderm) in  
645 day 8 blastocysts under the treatment in Exp.1 and Exp. 2. Scale bar, 50  $\mu\text{m}$ . **C.** Ratio of  
646 SOX17<sup>+</sup> and SOX2<sup>+</sup> cells in embryos from Exp. 1-3. **D.** Developmental rates of embryos under  
647 Control or treatments. **E.** Immunofluorescence analysis of SOX17, SOX2, and CDX2 in day 12  
648 embryos under the treatment in Exp. 3. Scale bar, 25  $\mu\text{m}$ . **F.** Schematic summarizing the impact  
649 of hypoblast on maintenance or differentiation of epiblast. Data are presented as the mean  $\pm$   
650 SEM. \* $P < 0.05$  from unpaired t-test.

651

652 **Figure 5. Generation of bovine blastocyst-like structures by self-organization of bXENs,**  
653 **bEPSCs, and bTSCs.** **A-D.** Top panel: Illustration of the bovine blastoid formation using  
654 different assembly approach (**A:** bEPSCs, bTSCs, and bXENs aggregation in FACLP medium;  
655 **B:** bEPSCs, bTSCs, and bXENs aggregation in ACL medium; **C:** bEPSCs and bTSCs  
656 aggregation in FACLP medium as our previous published, as well as the IVF blastocysts control.  
657 Bottom panel: Phase-contrast and immunofluorescence analysis of blastoids from distinct  
658 protocols and blastocysts, as well as the quantification of lineage composition. Green, SOX17;  
659 Blue, SOX2; Red, CDX2. **E.** Blastoid foration rate from distinct protocols. **F.** Blastocoele diameter  
660 measurement of blastoids from distinct protocols and blastocysts. **G.** Inner cell mass  
661 (ICM)/embryo ratio measurement of blastoids from distinct protocols, as well as blastocysts. **H.**  
662 Joint uniform manifold approximation and projection (UMAP) embedding of 10X Genomics  
663 single-nucleus transcriptomes of bovine 3L-blastoids (green) and bovine day 8 blastocyst (blue).  
664 **I.** Major cluster classification based on marker expression. **J.** Dot plot indicating the expression  
665 of markers of epiblast, trophectoderm, and hypoblast. **K.** Percentage of three cell types in  
666 blastoid and blastocyst. Data are presented as the mean $\pm$ SEM. \* $P < 0.05$  from one-way  
667 analysis of variance (ANOVA) followed by Tukey's multiple comparisons test.

668

669

## 670 **Supplementary Figures and Tables**

671

672 **Table S1.** Culture conditions screened for the derivation of bovine XENs.

673

674 **Figure S1. Derivation and characterization of bXEN<sup>S</sup> cells.** **A.** Representative image of  
675 outgrowth that formed from day 8 bovine blastocyst and subsequent generations of bXEN<sup>S</sup>. **B.**  
676 UMAP analysis of transcriptomic dataset of day 12 *in vivo* embryos (Scatolin et al., iScience,  
677 2024) revealing four distinct cell types identified as epiblast (EPI), hypoblast (HP),  
678 trophectoderm (TE), and intermediate (Int) cells. Dot plot representing the expression of gene

679 markers for Epi, HP, and TE. Dot size represents the percentage of cells in the cluster  
680 expressing the gene markers, the color gradient represents the level of expression from high  
681 (red) to low (yellow). **C.** UMAPs analysis showing the expression levels of selected hypoblast  
682 markers (*CTSV*, *FETUB*, *APOA1*, *APOE*, *COL4A1*, *FN1*) in day 12 *in vivo* embryos among all  
683 clusters. The color gradient from gray to blue at the right refers to the gene expression level  
684 (high expression = blue). **D.** Relative expression of defined lineage marker genes in three cell  
685 lines. Data are presented as the mean $\pm$ SEM. \* $P < 0.05$  from one-way analysis of variance  
686 (ANOVA) followed by Tukey's multiple comparisons test.

687

688 **Figure S2. Transcriptional and epigenomic features of bovine XENs.** **A.** Heatmap showing  
689 the correlation between bXEN, bEPSC, and bTSC. The color gradient represents the level of  
690 correlation from high (red) to low (blue). **B.** Heatmap showing overlapped XEN enriched genes  
691 among human, mouse, and bovine. **C.** The genome browser views showing the ATAC-seq  
692 peaks and RNA-seq reads enrichment near *NFYA*, *NFYC*, *CTCF* and *JUND* in bXENs. **D.**  
693 UMAPs showing the expression levels of specific transcription factors (*NFYA*, *NFYC*, *CTCF* and  
694 *JUND*) in day 12 *in vivo* embryos among all clusters. The color gradient from gray to purple at  
695 the right refers to the gene expression level (high expression = purple). Data are presented as  
696 the mean  $\pm$  SEM. \* $P < 0.05$  from one-way analysis of variance (ANOVA) followed by Tukey's  
697 multiple comparisons test.

698

699 **Figure S3. Immunofluorescence analysis of GATA6 (hypoblast), SOX2 (epiblast), as well**  
700 **as CDX2 (trophectoderm) in day 12 *in vivo* embryos.** Scale bar, 100 $\mu$ m.

701

702 **Figure S4. Single cell RNA-seq analysis of blastoid and blastocyst.** **A.** UMAP showing  
703 expression of trophoctoderm (*GATA2*), hypoblast (*PDGFRA*), and epiblast markers (*SLIT2*),  
704 respectively. **B.** Heatmap showing the expression of cell lineage-specific genes in epiblast,  
705 trophoctoderm, and hypoblast, as well as the biological functions regulated by the genes,  
706 separately.

707

## 708 References


- 709 1. A. T. Moerkamp *et al.*, Extraembryonic endoderm cells as a model of endoderm  
710 development. *Dev Growth Differ* **55**, 301-308 (2013).
- 711 2. G. J. Burton, A. L. Watson, J. Hempstock, J. N. Skepper, E. Jauniaux, Uterine glands  
712 provide histiotrophic nutrition for the human fetus during the first trimester of pregnancy.  
713 *J Clin Endocrinol Metab* **87**, 2954-2959 (2002).
- 714 3. G. J. Burton, J. Hempstock, E. Jauniaux, Nutrition of the human fetus during the first  
715 trimester--a review. *Placenta* **22 Suppl A**, S70-77 (2001).
- 716 4. A. C. Assis Neto *et al.*, Morpho-physical recording of bovine conceptus (*Bos indicus*) and  
717 placenta from days 20 to 70 of pregnancy. *Reprod Domest Anim* **45**, 760-772 (2010).
- 718 5. A. C. Assis Neto, E. C. Santos, F. T. Pereira, M. A. Miglino, Initial development of bovine  
719 placentation (*Bos indicus*) from the point of view of the allantois and amnion. *Anat Histol*  
720 *Embryol* **38**, 341-347 (2009).
- 721 6. N. C. Talbot *et al.*, Isolation and characterization of a bovine visceral endoderm cell line  
722 derived from a parthenogenetic blastocyst. *In Vitro Cell Dev Biol Anim* **41**, 130-141  
723 (2005).
- 724 7. G. N. Scatolin *et al.*, Single-cell transcriptional landscapes of bovine peri-implantation  
725 development. *iScience* **27**, 109605 (2024).
- 726 8. L. D. Dunne, M. G. Diskin, J. M. Sreenan, Embryo and foetal loss in beef heifers  
727 between day 14 of gestation and full term. *Anim Reprod Sci* **58**, 39-44 (2000).
- 728 9. D. M. Henricks, D. R. Lamond, J. R. Hill, J. F. Dickey, Plasma progesterone  
729 concentrations before mating and in early pregnancy in the beef heifer. *J Anim Sci* **33**,  
730 450-454 (1971).
- 731 10. M. G. Diskin, J. M. Sreenan, Fertilization and embryonic mortality rates in beef heifers  
732 after artificial insemination. *J Reprod Fertil* **59**, 463-468 (1980).
- 733 11. J. Rossant, Stem cells and early lineage development. *Cell* **132**, 527-531 (2008).
- 734 12. T. Kunath *et al.*, Imprinted X-inactivation in extra-embryonic endoderm cell lines from  
735 mouse blastocysts. *Development* **132**, 1649-1661 (2005).
- 736 13. C. H. Park *et al.*, Extraembryonic Endoderm (XEN) Cells Capable of Contributing to  
737 Embryonic Chimeras Established from Pig Embryos. *Stem Cell Reports* **16**, 212-223  
738 (2021).
- 739 14. M. L. Zhang *et al.*, Derivation of Porcine Extra-Embryonic Endoderm Cell Lines Reveals  
740 Distinct Signaling Pathway and Multipotency States. *Int J Mol Sci* **22** (2021).
- 741 15. Y. Wei *et al.*, Dissecting embryonic and extraembryonic lineage crosstalk with stem cell  
742 co-culture. *Cell* **186**, 5859-5875 e5824 (2023).
- 743 16. M. Linneberg-Agerholm *et al.*, Naive human pluripotent stem cells respond to Wnt, Nodal  
744 and LIF signalling to produce expandable naive extra-embryonic endoderm.  
745 *Development* **146** (2019).
- 746 17. L. T. Cho *et al.*, Conversion from mouse embryonic to extra-embryonic endoderm stem  
747 cells reveals distinct differentiation capacities of pluripotent stem cell states.  
748 *Development* **139**, 2866-2877 (2012).
- 749 18. A. Dattani *et al.*, Naive pluripotent stem cell-based models capture FGF-dependent  
750 human hypoblast lineage specification. *Cell Stem Cell* **31**, 1058-1071 e1055 (2024).
- 751 19. T. Okubo *et al.*, Hypoblast from human pluripotent stem cells regulates epiblast  
752 development. *Nature* **626**, 357-366 (2024).
- 753 20. Q. E. Yang *et al.*, Fibroblast growth factor 2 promotes primitive endoderm development  
754 in bovine blastocyst outgrowths. *Biol Reprod* **85**, 946-953 (2011).
- 755 21. M. K. Smith, C. C. Clark, S. R. McCoski, Technical note: improving the efficiency of  
756 generating bovine extraembryonic endoderm cells. *J Anim Sci* **98** (2020).

- 757 22. L. Zhao *et al.*, Establishment of bovine expanded potential stem cells. *Proc Natl Acad*  
758 *Sci U S A* **118** (2021).
- 759 23. Y. Wang *et al.*, Establishment of bovine trophoblast stem cells. *Cell Rep*  
760 10.1016/j.celrep.2023.112439, 112439 (2023).
- 761 24. C. A. Pinzon-Arteaga *et al.*, Bovine blastocyst-like structures derived from stem cell  
762 cultures. *Cell Stem Cell* **30**, 611-616 e617 (2023).
- 763 25. Y. Wang *et al.*, Establishment of bovine trophoblast stem cells. *Cell Rep* **42**, 112439  
764 (2023).
- 765 26. Y. Zhong *et al.*, Isolation of primitive mouse extraembryonic endoderm (pXEN) stem cell  
766 lines. *Stem Cell Res* **30**, 100-112 (2018).
- 767 27. T. E. Spencer, N. Forde, P. Lonergan, Insights into conceptus elongation and  
768 establishment of pregnancy in ruminants. *Reprod Fertil Dev* **29**, 84-100 (2016).
- 769 28. B. A. T. Weatherbee *et al.*, Pluripotent stem cell-derived model of the post-implantation  
770 human embryo. *Nature* **622**, 584-593 (2023).
- 771 29. E. W. Kuijk *et al.*, The roles of FGF and MAP kinase signaling in the segregation of the  
772 epiblast and hypoblast cell lineages in bovine and human embryos. *Development* **139**,  
773 871-882 (2012).
- 774 30. J. Rossant, P. P. L. Tam, New Insights into Early Human Development: Lessons for Stem  
775 Cell Derivation and Differentiation. *Cell Stem Cell* **20**, 18-28 (2017).
- 776 31. J. R. Canizo *et al.*, A dose-dependent response to MEK inhibition determines hypoblast  
777 fate in bovine embryos. *BMC Dev Biol* **19**, 13 (2019).
- 778 32. H. Ming *et al.*, In vitro culture alters cell lineage composition and cellular metabolism of  
779 bovine blastocystdagger. *Biol Reprod* **111**, 11-27 (2024).
- 780 33. C. Ross, T. E. Boroviak, Origin and function of the yolk sac in primate embryogenesis.  
781 *Nat Commun* **11**, 3760 (2020).
- 782 34. J. Xiang *et al.*, LCDM medium supports the derivation of bovine extended pluripotent  
783 stem cells with embryonic and extraembryonic potency in bovine-mouse chimeras from  
784 iPSCs and bovine fetal fibroblasts. *FEBS J* **288**, 4394-4411 (2021).
- 785 35. M. Linneberg-Agerholm *et al.*, The primitive endoderm supports lineage plasticity to  
786 enable regulative development. *Cell* **187**, 4010-4029 e4016 (2024).
- 787 36. X. Liu *et al.*, Modelling human blastocysts by reprogramming fibroblasts into iBlastoids.  
788 *Nature* **591**, 627-632 (2021).
- 789 37. L. Yu *et al.*, Blastocyst-like structures generated from human pluripotent stem cells.  
790 *Nature* **591**, 620-626 (2021).
- 791 38. H. Kagawa *et al.*, Human blastoids model blastocyst development and implantation.  
792 *Nature* **601**, 600-605 (2022).
- 793 39. C. Zhao *et al.*, Reprogrammed blastoids contain amnion-like cells but not trophectoderm.  
794 *bioRxiv* 10.1101/2021.05.07.442980, 2021.2005.2007.442980 (2021).
- 795 40. G. Amadei *et al.*, Embryo model completes gastrulation to neurulation and  
796 organogenesis. *Nature* **610**, 143-153 (2022).
- 797 41. K. Y. C. Lau *et al.*, Mouse embryo model derived exclusively from embryonic stem cells  
798 undergoes neurulation and heart development. *Cell Stem Cell* **29**, 1445-1458 e1448  
799 (2022).
- 800 42. T. Stuart *et al.*, Comprehensive Integration of Single-Cell Data. *Cell* **177**, 1888-1902  
801 e1821 (2019).
- 802 43. G. Yu, L. G. Wang, Y. Han, Q. Y. He, clusterProfiler: an R package for comparing  
803 biological themes among gene clusters. *OMICS* **16**, 284-287 (2012).
- 804 44. D. Kim, J. M. Paggi, C. Park, C. Bennett, S. L. Salzberg, Graph-based genome  
805 alignment and genotyping with HISAT2 and HISAT-genotype. *Nat Biotechnol* **37**, 907-  
806 915 (2019).



- 807 45. M. D. Robinson, D. J. McCarthy, G. K. Smyth, edgeR: a Bioconductor package for  
808 differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139-  
809 140 (2010).
- 810 46. B. Langmead, S. L. Salzberg, Fast gapped-read alignment with Bowtie 2. *Nat Methods* **9**,  
811 357-359 (2012).
- 812 47. J. T. Robinson *et al.*, Integrative genomics viewer. *Nat Biotechnol* **29**, 24-26 (2011).
- 813 48. S. Heinz *et al.*, Simple combinations of lineage-determining transcription factors prime  
814 cis-regulatory elements required for macrophage and B cell identities. *Mol Cell* **38**, 576-  
815 589 (2010).
- 816 49. Y. Liao, G. K. Smyth, W. Shi, featureCounts: an efficient general purpose program for  
817 assigning sequence reads to genomic features. *Bioinformatics* **30**, 923-930 (2014).
- 818 50. Y. Zhang *et al.*, Model-based analysis of ChIP-Seq (MACS). *Genome Biol* **9**, R137  
819 (2008).
- 820 51. P. Danecek *et al.*, Twelve years of SAMtools and BCFtools. *Gigascience* **10** (2021).
- 821 52. H. Ming *et al.*, The landscape of accessible chromatin in bovine oocytes and early  
822 embryos. *Epigenetics* **16**, 300-312 (2021).
- 823 53. Y. Chen *et al.*, A versatile polypharmacology platform promotes cytoprotection and  
824 viability of human pluripotent and differentiated cells. *Nat Methods* **18**, 528-541 (2021).
- 825

Figure 1





**Figure 3**




Figure 4






Figure 5

